For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Cisplatin Modified Native DNA.
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
Our Abpromise guarantee covers the use of ab103261 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration. PubMed: 23370278Ab37371-Rat monoclonal IgG, is suitable for use as an isotype control with this antibody.
ab37371-Rat polyclonal IgG, is suitable for use as an isotype control with this antibody.
|Dot blot||Use at an assay dependent concentration. PubMed: 25356874|
ab103261 staining Cisplatin modified DNA in human ovarian cancer cell line A2780 by Flow Cytometry. Cells in culture were detached by accutase treatment, fixed with 70% ehtanol for 30 min at 4°C and permeabilized with 100ug/ml digitonin in PBS. The sample was incubated with the primary antibody (1/200 in PBS + 1% FBS) for 18 hours at 4°C. A FITC-conjugated rabbit anti-rat IgG H&L polyclonal (1/200) was used as the secondary antibody. Gating Strategy: FITC positive cells.
The sh2 represents the gene knock down cell line which showed positive staining with anti-cisplatin adduct antibody upon cisplatin treatment, whereas the control cells (cis-R, resistant to cisplatin) did not show any staining with anti-cis adduct antibody upon cisplatin treatment.